Identifying microRNAs in septic acute kidney injury
Specific miRNA Associated With Endothelial Dysfunction and Mitochondrial Damage in Patients With Septic Acute Kidney Injury
This study is trying to see if certain tiny molecules in the blood can help doctors understand and treat kidney injury caused by sepsis in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 220 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | University Hospital Ostrava Academic / other |
| Locations | 2 sites (Ostrava, Moravian-Silesian Region and 1 other locations) |
| Trial ID | NCT06498336 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the role of specific microRNAs in the pathophysiological mechanisms of septic acute kidney injury (AKI). It focuses on patients diagnosed with sepsis, with or without AKI, and healthy volunteers to compare biomarker levels. The study will involve laboratory examinations to assess the presence of sepsis, AKI, and relevant microRNA and biochemical parameters. By understanding these mechanisms, the research seeks to establish new diagnostic or therapeutic targets for septic AKI.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old who have been newly diagnosed with sepsis or septic shock, with or without acute kidney injury.
Not a fit: Patients under 18 years old, those with chronic kidney disease stage 4 or 5, or individuals on chronic dialysis or after renal transplantation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and therapeutic strategies for patients suffering from septic acute kidney injury.
How similar studies have performed: While the specific approach of identifying microRNAs in septic AKI is novel, related studies have shown promise in exploring biomarkers for sepsis and AKI.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: The study group of patients with sepsis with or without acute kidney injury * age \> 18 years * newly diagnosed sepsis or septic shock with or without acute kidney injury Healthy volunteers * no evidence of infection on clinical or laboratory examination * age \> 18 years * signed informed consent Exclusion Criteria: The study group of patients with sepsis with or without acute kidney injury * age \< 18 years * chronic kidney disease at stage 4 or 5 according to KDIGO recommendations (KDIGO) for chronic kidney disease 2024 * patients on chronic dialysis treatment, or after renal transplantation Healthy volunteers * acute or chronic infection * renal disease
Where this trial is running
Ostrava, Moravian-Silesian Region and 1 other locations
- University Hospital Ostrava — Ostrava, Moravian-Silesian Region, Czechia (Recruiting)
- University Hospital Olomouc — Olomouc, Olomouc Region, Czechia (Recruiting)
Study contacts
- Principal investigator: Naděžda Petejová, Assoc.Prof.,MD,PhD,MSc — University Hospital Ostrava
- Study coordinator: Jiří Hynčica
- Email: jiri.hyncica@gmail.com
- Phone: 0042059737
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.